No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 873 | 1,188 | 1,576 | 1,352 | 1,338 | 1,242 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | -9 | 50 | 43 | 11 | 11 | -39 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
H&R GmbH & Co. KGaA is a German enterprise specializing in the production and distribution of chemical-pharmaceutical raw materials and precision plastic components, manufactured through injection molding. The company's operations are structured into three primary segments: ChemPharm Refining, ChemPharm Sales, and Plastics. The ChemPharm Refining division is responsible for manufacturing and supplying a diverse array of refined products, including paraffins, white oils, plasticizers, base oils, lubricants, and other specialized crude oil derivatives, as well as feedstocks and bunker fuels. Concurrently, the ChemPharm Sales segment focuses on the processing and commercialization of products such as plasticizers, wax emulsions, paraffins, and similar crude oil-based specialty items. The Plastics division is dedicated to the development, production, and sale of high-precision plastic parts tailored for industries like medical technology, automotive, and various other sectors. H&R's extensive product portfolio also encompasses petroleum jellies, different types of motor and process oils, cable filling compounds, ozone protection waxes, raw materials for the cosmetic and pharmaceutical sectors, mineral oils, and construction insulation materials. Founded in 1919 and headquartered in Salzbergen, Germany, the company transitioned its name to H&R GmbH & Co. KGaA in August 2016, having previously operated as H&R Aktiengesellschaft. It functions as a subsidiary of H&R Komplementär GmbH.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
H&R GmbH & Co. KGaA (2HRA.DE)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
H&R GmbH & Co. KGaA is a German enterprise specializing in the production and distribution of chemical-pharmaceutical raw materials and precision plastic components, manufactured through injection molding. The company's operations are structured into three primary segments: ChemPharm Refining, ChemPharm Sales, and Plastics. The ChemPharm Refining division is responsible for manufacturing and supplying a diverse array of refined products, including paraffins, white oils, plasticizers, base oils, lubricants, and other specialized crude oil derivatives, as well as feedstocks and bunker fuels. Concurrently, the ChemPharm Sales segment focuses on the processing and commercialization of products such as plasticizers, wax emulsions, paraffins, and similar crude oil-based specialty items. The Plastics division is dedicated to the development, production, and sale of high-precision plastic parts tailored for industries like medical technology, automotive, and various other sectors. H&R's extensive product portfolio also encompasses petroleum jellies, different types of motor and process oils, cable filling compounds, ozone protection waxes, raw materials for the cosmetic and pharmaceutical sectors, mineral oils, and construction insulation materials. Founded in 1919 and headquartered in Salzbergen, Germany, the company transitioned its name to H&R GmbH & Co. KGaA in August 2016, having previously operated as H&R Aktiengesellschaft. It functions as a subsidiary of H&R Komplementär GmbH.